CA-CROWN-BIOSCIENCE
Crown Bioscience, a JSR Life Sciences company, today announces the opening of a new oncology-focused research facility in Zhongshan, China to satisfy increased customer demand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005098/en/
In addition to the Company’s four facilities across the US and Europe, CrownBio’s existing APAC footprint currently includes three sites located in Beijing, Taicang, and Suzhou, as well as one in Taiwan. Once completed, this new building will add more than 2,000m2 of new vivarium space to support CrownBio’s in vivo oncology platforms, helping satisfy predicted near-term growth.
CrownBio’s world-leading products and services are used by pharmaceutical and biotech customers across APAC, North America, and Europe to accelerate and de-risk their drug discovery programs. With the significant and continued growth of CrownBio’s client base, the Zhongshan facility has been purpose built to meet expanding study needs.
The research and drug development facility features BSL-2 laboratories and will include a state-of-the-art ABSL-2 vivarium. Initial capabilities will focus on expanding cell line-derived xenograft model availability and study throughput, with an increased roster of cutting edge, translational oncology models becoming available. Full operational capacity is expected in early 2021.
“The establishment of our new Zhongshan facility demonstrates our continued commitment to our clients, to provide sustained rapid study initiation combined with robust cost-effectiveness,” said John Gu, chief operating officer at CrownBio. “Through our growth, we can more fully support our clients in their goals of more rapid and efficient cancer drug development”.
A site opening event and ribbon cutting ceremony will take place on October 30th 2020.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
● https://www.jsrlifesciences.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005098/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Paymentology Launches PayCredit to Power Credit Innovation for Digital Banks and Fintechs22.10.2025 10:00:00 CEST | Press release
The new credit solution integrates card issuing and credit ledger management, helping issuers reduce complexity and accelerate time to market. Paymentology, the leading global issuer-processor, has launched PayCredit, an advanced credit ledger platform designed to help financial institutions deliver tailored, feature rich credit products at speed, overcoming the limitations of legacy and core banking systems. Amid rising demand for flexible financial payment tools, credit cards remain a critical instrument for enabling consumer spending, managing cash flow, and deepening customer loyalty. Yet many legacy credit systems lack the flexibility to meet the expectations of today's consumers, who demand a combination of both revolving and instalment credit to help them better manage their money, whilst many modern ledgers are retrofitted from a debit architecture and struggle to provide credit processing. PayCredit was developed from the ground up with credit billing cycles and logic at its c
Infrastructure Capital Advisors Expands its Offerings into European Markets With Launch of Preferred Income UCITS ETF (PFFI) & Declares The Fund’s First Dividend22.10.2025 10:00:00 CEST | Press release
PFFI is now listed on the LSE, Xetra and Borsa Italiana Exchanges and registered in 11 European markets Infrastructure Capital Advisors (“Infrastructure Capital”), a leading provider of investment management solutions designed to meet the needs of income-focused investors, is celebrating the expansion of its offerings into Europe with the launch of the Infrastructure Capital Preferred Income UCITS ETF (PFFI). This actively managed ETF, which was listed in September, seeks to produce diversified income by targeting high yield income investments by predominately focusing on preferred stocks. Today,PFFI is also declaring its first dividend of $0.1335 per share ($1.602 per share on an annualized basis). The dividend will be paid on November 3, 2025 to shareholders of record as of the close of business on October 29, 2025. “We are thrilled to offer investors across a range of global markets the opportunity to benefit from our team’s active management process applied to preferred and income
Locus Robotics Reports Record Growth Achieving 6 Billion Picks in Fastest Time Yet22.10.2025 10:00:00 CEST | Press release
Accelerating adoption, rapid customer ROI, and consecutive record quarters fuel positive market momentum Locus Robotics, the global leader in AI-driven, mobile warehouse automation, today announced its strongest growth over the past two quarters, reflecting accelerating industry adoption of Physical AI, seamlessly fusing intelligent robotics and real-world execution. Driven by surging implementations and faster time-to-value for customers, Locus Robotics recently surpassed 6 billion picks worldwide, with the last billion in just 24 weeks—the fastest pace in its history. “Our growth is driven by our customers’ success,” said Rick Faulk, CEO of Locus Robotics. “Retailers, 3PLs, and healthcare providers are seeing measurable impact faster than ever—scaling productivity in weeks, not months. Staples Canada, for example, hit one million picks just 70 days after going live, proving the immediate ROI our platform delivers.” So far this year, Locus Robotics has seen 30–40% year-over-year volum
Smartstream and ActiveViam Collaborate to Meet Demands for Collateral Optimisation22.10.2025 09:55:00 CEST | Press release
Key Facts Smartstream and ActiveViam have partnered to deliver an integrated solution combining Smartstream’s Smart Collateral with ActiveViam’s Atoti Collateral Optimisation platform. The collaboration enables financial institutions to optimise collateral allocation, reduce reliance on costly liquidity buffers, and achieve immediate return on investment. The modular, high-performance solution supports regulatory compliance (UMR, EMIR, Basel III) and empowers clients to make smarter use of their collateral inventory. Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces the partnership with ActiveViam, a global provider of advanced data analytics and decision-making solutions for financial services – together the two companies will provide immediate ROI for collateral management optimisation, for clients in treasury and capital markets. This collaboration connects two technologies, Smartstream’s Smart Collateral with
Global Registry Data Show Meaningful Overall Survival Benefit in Patients with Advanced Cutaneous T-cell Lymphoma (CTCL) treated with POTELIGEO (mogamulizumab)22.10.2025 09:30:00 CEST | Press release
The PROCLIPI study, one of the largest studies to date in cutaneous T-cell lymphoma (CTCL), is a prospective, observational, multicentre international registry spanning 19 countries and includes over 2,000 patients, collects data to develop prognostic indices for CTCL1An analysis of 371 patients observed meaningful overall survival (OS) benefit for patients with advanced mycosis fungoides (MF) and Sézary syndrome (SS) treated with POTELIGEO (mogamulizumab)1,2,3Findings align with earlier survival signals and highlight how global collaboration can generate meaningful evidence in rare conditions such as MF and SS4,5Results were presented at this year’s European Organisation for Research and Treatment of Cancer - Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting in Athens, Greece2 Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and the University Hospitals Birmingh
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom